Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

This study is a an open-label, multinational, multicenter, single-arm Phase Ⅰb/Ⅱ Study to Evaluate Efficacy and Safety of Oral HH2853 in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma.

Trial Details

NCT ID
NCT06909877
Phase
PHASE1 / PHASE2
Sponsor
Haihe Biopharma Co., Ltd.
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • HH2853 Tablets
Locations (sample)
  • Chengdu, Chengdu, China|30.66667,104.06667

Key Eligibility Criteria

  • main inclusion:
  • Tumor types and prior antitumor therapy: Phase Ib:Dose Escalation: All enrolled patients must have histologically confirmed diagnosis NHL who have …
  • Availability of qualified tissue samples by patient for pathological diagnosis by the central laboratory.
  • The Eastern cooperative oncology group (ECOG) score 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →